Leucine-rich repeat kinase 2 gene-associated disease: Redefining genotype-phenotype correlation

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 175-179

  Wider, Christian ^a   Dickson, Dennis W ^a   Wszolek, Zbigniew K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Leucine rich repeat kinase 2gene; Lewy body disease; Nigral degeneration; Parkinson's disease; Progressive supranuclear gaze palsy

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; TAU PROTEIN; UBIQUITIN;

AUTONOMIC DYSFUNCTION; AUTOPSY; CONFERENCE PAPER; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; THERAPY RESISTANCE; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; TAU PROTEINS; UBIQUITIN;

EID: 77449098331     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000289232     Document Type: Conference Paper

References (25)

1. Farrer MJ: Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006; 7: 306-318.
2. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
3. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ, Zimprich A, Muller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62: 1619-1622.
4. Ross OA, Toft M, Haugarvoll K: Corticobasal syndrome and primary progressive aphasia as manifestations of lrrk2 gene mutations. Neurology 2008; 71: 303; author reply 303-304.
5. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW: Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-590.
6. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V: A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006; 7: 133-138.
7. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI, Mata IF, Lee-Chen GJ, Chen CM, Tang M, Zhao Y, Hattori N, Farrer MJ, Tan EK, Wu RM: Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 2008; 64: 88-92.
8. Wszolek ZK, Pfeiffer B, Fulgham JR, Parisi JE, Thompson BM, Uitti RJ, Calne DB, Pfeiffer RF: Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995; 45: 502-505.
9. Wszolek ZK, Vieregge P, Uitti RJ, Gasser T, Yasuhara O, McGeer P, Berry K, Calne DB, Vingerhoets FJ, Klein C, Pfeiffer RF: German- Canadian family (family A) with parkinsonism, amyotrophy, and dementia - longitudinal observations. Parkinsonism Relat Disord 1997; 3: 125-139.
10. Chen-Plotkin AS, Yuan W, Anderson C, Mc- Carty Wood E, Hurtig HI, Clark CM, Miller BL, Lee VM, Trojanowski JQ, Grossman M, Van Deerlin VM: Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 2008; 70: 521-527.
11. Spanaki C, Latsoudis H, Plaitakis A: LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 2006; 67: 1518-1519.
12. Dachsel JC, Ross OA, Mata IF, Kachergus J, Toft M, Cannon A, Baker M, Adamson J, Hutton M, Dickson DW, Farrer MJ: Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol 2007; 113: 601-606.
13. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ: Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006; 67: 1506-1508.
14. Gaig C, Ezquerra M, Marti MJ, Valldeoriola F, Munoz E, Llado A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E: Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 2008; 270: 94-98.
15. Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E: G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry 2007; 78: 626-628.
16. Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S: Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 2009; 15: 300-306.
17. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM: Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006; 59: 315-322.
18. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW: A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365: 415-416.
19. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW: Lrrk2 and Lewy body disease. Ann Neurol 2006; 59: 388-393.
20. Khan NL, Jain S, Lynch JM, Pavese N, Abou- Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW: Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005; 128: 2786-2796.
21. Santpere G, Ferrer I: LRRK2 and neurodegeneration. Acta Neuropathol 2009; 117: 227-246.
22. Devine MJ, Lewis PA: Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. FEBS J 2008; 275: 5748-5757.
23. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ: A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007; 147: 1047-1058.
24. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM: Parkinson's disease- associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007; 16: 223-232.
25. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR: LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007; 405: 307-317.